Danaher Corporation (DHR) Stock

Danaher Corporation (DHR) is a Technology stock trading at $215.99 (as of 2026-08-20), with a market capitalization of $151.84B and a trailing P/E of 37.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. It operates through Life Sciences and Diagnostics segments, offering instruments, reagents, consumables, software, and services for laboratory and healthcare settings, and also reports an Environmental & Applied Solutions segment.

Understand Danaher Corporation: how it makes money

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide, earning revenue from its three reporting segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Diversified segment revenue, supported by Danaher's ability to sell products and services across Life Sciences, Diagnostics, and Environmental & Applied Solutions, with Life Sciences explicitly including consumables and services alongside core technologies.

Revenue by segment (latest quarter)
Life Sci$2.1B
Diagnostics$2.7B
Env & Applied$1.3B

Business quality (Mixed): Latest reported results show revenue of about $6.0B, with gross margin of 60.3% and operating margin of 22.6%, suggesting the company converts sales into meaningful operating profit while operating through three diversified segments.

Valuation: At 35× earnings, DHR trades 42% below the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

  • Diversification by reporting segment: Diagnostics (2.72B) and Life Sciences (2.08B) are both sizable contributors, with Environmental & Applied Solutions also contributing (1.25B).
  • Strong profitability in the latest period: Gross margin was 60.3% and operating margin was 22.6% for the period ending 2026-03-27.

Bear case

  • Exposure to performance in specific segments: Diagnostics accounts for a large share of segment revenue (2.72B versus total revenue of about 6.0B), so weaker demand or execution in Diagnostics could pressure results.
  • Product and application concentration risk: Within the provided operating metric set, respiratory testing revenue is shown (0.75B), including Cepheid respiratory revenue (0.5B), which suggests some exposure is tied to specific testing applications.
Valuation — source: SEC EDGAR (first-party)
Price$215.99
Market Cap$151.84B
P/E Ratio37.9
EV / EBITDA29.5
Price / Book2.89
Price / Sales6.05
FCF Yield3.6%
DCF Value (model)$28.92
DCF Upside vs Price-86.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$24.57B
Net Margin14.7%
Revenue Growth (YoY)5.5%
EPS Growth (YoY)59.7%
FCF Growth (YoY)16.1%
Financial Health — source: SEC EDGAR
Altman Z-Score4.32 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E37.9
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
vs Sector11.8%
vs Industry-26.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($13.96B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEORainer Blair
Employees61,000
CountryUS
IPO Date1978-12-29

Related Companies (Business model: Medical Devices / Life Science Tools + Industrials / Capital Goods (Heavy Machinery + Diversified Industrials); 8 closest by market cap; US-domiciled)

  • Thermo Fisher Scientific Inc. (TMO)
  • Rockwell Automation, Inc. (ROK)
  • Waters Corporation (WAT)
  • Illumina, Inc. (ILMN)
  • Mettler-Toledo International Inc. (MTD)
  • MKS Inc. (MKSI)
  • Fortive Corporation (FTV)
  • Ralliant Corp. (RAL)
DHR earnings history · DHR institutional & insider holders · DHR KPIs & operating metrics · DHR financials · DHR investor presentations & press releases · DHR SEC filings · DHR peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.